Details for Patent: 7,825,116

Title:	N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines
Abstract:	The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
Inventor(s):	Singh; Rajinder (Belmont, CA), Argade; Ankush (Foster City, CA), Payan; Donald G. (Hillsborough, CA), Clough; Jeffrey (Redwood City, CA), Keim; Holger (Menlo Park, CA), Bhamidipati; Somasekhar (Foster City, CA), Sylvain; Catherine (San Mateo, CA), Li; Hui (Millbrae, CA)
Assignee:	Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Filing Date:	Oct 05, 2006
Application Number:	11/539,101
Claims:	1. A compound according to formula: ##STR00053## or a pharmaceutically acceptable salt thereof, wherein: X is halo; R is selected from the group consisting of hydrogen, (C.sub.1-C.sub.3)alkyl, arylalkyl, --CH.sub.2C(O)OMe, --CH.sub.2C(O)NH(C.sub.1-C.sub.3)alkyl, --CH.sub.2CH.sub.2OH, perhaloalkyl, and (C.sub.3-C.sub.8)cycloalkyl optionally substituted with --NH.sub.2, --NHEt, or --NHBoc; R.sup.1 is selected from the group consisting of hydrogen, (C.sub.1-C.sub.3)alkyl, and halo; R.sup.2 is selected from the group consisting of: phenyl substituted with one or three of the same or different R.sup.8 groups wherein each R.sup.8 is independently selected from the group consisting of halo, --(C.sub.1-C.sub.3)alkyl, --O(C.sub.1-C.sub.3)alkyl, --O(arylalkyl), --OCH.sub.2C(O)NH--(C.sub.3-C.sub.8)cycloalkyl, (C.sub.1-C.sub.3)perhaloalkyl, (C.sub.1-C.sub.3)perhaloalkoxy, --OCH.sub.2C(O)NHCH.sub.2CH.sub.2NH.sub.2, --C(O)NH.sub.2, --CH.sub.2NH.sub.2, --CH.sub.2NHBoc, and a heteroaryl selected from the group consisting of ##STR00054## 2. The compound of claim 1 according to formula: ##STR00055## wherein: p is 1 or 3; and each R.sup.8 is independently selected from the group consisting of halo, (C.sub.1-C.sub.3)alkyl, --O(C.sub.1-C.sub.3)alkyl, --O(arylalkyl), --OCH.sub.2C(O)NH--(C.sub.3-C.sub.8)cycloalkyl, (C.sub.1-C.sub.3)perhaloalkyl, (C.sub.1-C.sub.3)perhaloalkoxy, --OCH.sub.2C(O)NHCH.sub.2CH.sub.2NH.sub.2, --C(O)NH.sub.2, --CH.sub.2NH.sub.2, and --CH.sub.2NHBoc. 3. A compound according to formula: ##STR00056## or a pharmaceutically acceptable salt thereof, wherein: R.sup.2 is selected from the group consisting of phenyl optionally substituted with substituted with one, two or three of the same or different R.sup.8 groups wherein R.sup.8 is selected from the group consisting of halo, (C.sub.i-C.sub.3)alkyl, --O(C.sub.1-C.sub.3)alkyl, --CH.sub.2NH.sub.2, --CH.sub.2NHBoc, and a heteroaryl selected from the group consisting of ##STR00057## 4. A compound according to formula: ##STR00058## or a pharmaceutically acceptable salt thereof, wherein: X' is hydrogen or halo; p is an integer from 1 to 3; each R.sup.8 is independently selected from the group consisting of --O(C.sub.1-C.sub.3)alkyl, perhaloalkyl, --O(CH.sub.2)C(O)NHMe and --O(CH.sub.2)C(O)NH--(C.sub.3-C.sub.8)cycloalkyl; and each of R.sup.3 and R.sup.4 is independently selected from the group consisting of (C.sub.1-C.sub.3)alkyl and --C(O)(C.sub.1-C.sub.3)alkyl; or R.sup.3 and R.sup.4, together with the nitrogen atom to which they are bound, form a morpholinyl or piperazinyl group optionally substituted with --C(O)OMe. 5. The compound of claim 4 according to formula: ##STR00059## 6. A compound according to formula: ##STR00060## or a pharmaceutically acceptable salt thereof, wherein: p is an integer from 1 to 3; R.sup.5 is selected from the group consisting of hydrogen, --C(O)Me, and --C(O)NHMe; and each R.sup.8 is independently selected from the group consisting of halo, --OH, (C.sub.1-C.sub.3)alkyl, --O(C.sub.1-C.sub.3)alkyl and --O(CH2)C(O)NHMe. 7. A compound according to formula: ##STR00061## or a pharmaceutically acceptable salt thereof, wherein: p is an integer from 1 to 3; each of R.sup.6 and R.sup.7 is independently selected from the group consisting of hydrogen, methyl, --CH.sub.2CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NHMe, --CH.sub.2CH(OH)CH.sub.2OH; or R.sup.6 and R.sup.7, together with the nitrogen atom to which they are bound, form a morpholinyl or piperidinyl group; and each R.sup.8 is independently selected from the group consisting of --O(CH.sub.2)C(O)NHMe and --O(CH.sub.2)C(O)NHCH.sub.2CH.sub.2NH.sub.2. 8. The compound of claim 7 according to formula: ##STR00062##